Hdl in immune‐inflammatory responses: Implications beyond cardiovascular diseases

Abstract

High density lipoproteins (HDL) are heterogeneous particles composed by a vast array of proteins and lipids, mostly recognized for their cardiovascular (CV) protective effects. However, evidences from basic to clinical research have contributed to depict a role of HDL in the modulation of immune‐inflammatory response thus paving the road to investigate their involvement in other diseases beyond those related to the CV system. HDL‐C levels and HDL composition are indeed altered in patients with autoimmune diseases and usually associated to disease severity. At molecular levels, HDL have been shown to modulate the anti‐inflammatory potential of endothelial cells and, by controlling the amount of cellular cholesterol, to interfere with the signaling through plasma membrane lipid rafts in immune cells. These findings, coupled to observations acquired from subjects carrying mutations in genes related to HDL system, have helped to elucidate the contribution of HDL beyond cholesterol efflux thus posing HDL‐based therapies as a compelling interventional approach to limit the inflammatory burden of immune‐inflammatory diseases.